跳至主要内容
临床试验/NCT01489345
NCT01489345已完成1 期

A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Ono Pharma USA Inc1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
试验地点
1
主要终点
Safety and tolerability of ONO-2952 using vital signs, ECGs, laboratory tests, physical examinations, and incidence/severity of adverse events

研究概览

简要总结

The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy non-smoking male or female subjects (18-55 inclusive)
  • Body mass index (BMI) of 19-35 kg/m2 (inclusive)
  • For females, surgically sterilized, postmenopausal, or who are non- lactating and agree to use a double barrier method of contraception

排除标准

  • History or presence of clinically significant disease

研究组 & 干预措施

Arm 1: Experimental

Experimental

干预措施: ONO-2952 (Drug)

Arm 2: Placebo Comparator

Placebo Comparator

干预措施: ONO-2952 Matching Placebo (Drug)

结局指标

主要结局

Safety and tolerability of ONO-2952 using vital signs, ECGs, laboratory tests, physical examinations, and incidence/severity of adverse events

时间窗: 36 days

次要结局

  • Characterization of PK of ONO-2952 in plasma samples(36 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Multiple-Dose Study to Evaluate the Safety,... | 临床试验